Tiotropium 5μg via Respimat and 18μg via HandiHaler; efficacy and safety in Japanese COPD patients  by Ichinose, M. et al.
Respiratory Medicine (2010) 104, 228e236ava i lab le a t www.sc iencedi rec t .com
journa l homepage : www.e lsev ie r . com/ loca te / rmedTiotropium 5 mg via Respimat and 18 mg via
HandiHaler; efficacy and safety in Japanese
COPD patientsM. Ichinose a,*, T. Fujimoto b,d, Y. Fukuchi c,ea Wakayama Medical University, Wakayama, Japan
b Nippon Boehringer Ingelheim, Japan
c Juntendo University School of Medicine, Tokyo, Japan
Received 19 August 2009; accepted 17 November 2009
Available online 6 December 2009KEYWORDS
Bronchodilators;
COPD;
Inhalation devices;
Pharmacokinetics;
Tiotropium* Corresponding author at: Third Dep
Japan. Tel.: þ81 73 441 0619; fax: þ8
E-mail address: masakazu@wakaya
d Tsuyoshi Fujimoto, 2-1-1 Osaki, Sh
e Yoshinosuke Fukuchi, 2-9-8-901 Ho
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2009.11.011Summary
Background and objectives: To compare the efficacy and safety of tiotropium inhaled via
Respimat Soft Mist Inhaler, a multidose propellant-free inhaler and HandiHaler, a single-
dose dry powder inhaler, in a phase 2 study of Japanese COPD patients.
Methods: Patients with FEV1 70% predicted, FEV1/FVC 70% and a smoking history of >10
pack-years received tiotropium once daily via Respimat (5 mg) and HandiHaler (18 mg) for
4 weeks each in a randomised, double-blind, double-dummy, two-way crossover study. Lung
function, adverse events, pharmacokinetics and safety were assessed.
Results: Of 184 patients screened, 134 were evaluable. The trough FEV1 response on Day 29
showed Respimat to be non-inferior to HandiHaler (mean treatment difference, 0.008 L;
95% CI, 0.009 to þ0.024 L; p< 0.001). Peak and average FEV1 and FVC responses on Day 1
and Day 29 were very similar for the two treatments. Tiotropium plasma levels and excretion
kinetics showed a similar profile of systemic exposure for the two formulations of tiotropium.
Adverse events were reported by similar numbers of patients on each treatment, i.e. 27.9 and
30.6% in the Respimat and HandiHaler groups, respectively.
Conclusions: In Japanese patients with COPD, tiotropium Respimat 5 mg and tiotropium Han-
diHaler 18 mg showed a similar profile of efficacy, safety and pharmacokinetics.
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The anticholinergic agent tiotropium (Spiriva) is a potent
and long-acting bronchodilator whose clinical benefits
when used chronically for the maintenance treatment of
COPD have been established in several clinical studies.1e4
When taken as a once daily inhalation, tiotropium improves
lung function, reduces dyspnoea, reduces the incidence of
exacerbations and improves health-related quality of life in
patients with COPD.5e10 It also reduces hyperinflation 11,12
and improves exercise tolerance.12,13
Tiotropium is the first long-acting anticholinergic
approved for the treatment of COPD. It was first introduced in
capsule form for inhalation via theHandiHaler, a single-dose
dry powder inhaler (DPI), and this form of tiotropium was
given marketing approval in Japan in 2004. Recently, tio-
tropium has been introduced in a new inhaler device, the
Respimat Soft Mist Inhaler, a novel, multidose, propellant-
free inhaler that delivers a fineparticle fraction of over 65%.14
The Respimat inhaler generates a fine aerosol cloud that is
generated over a longer period and moves more slowly than
the aerosol from a pressurised metered-dose inhaler (pMDI).
Because the aerosol cloud lasts 4e10 times longer than a pMDI
aerosol,15 the Respimat inhaler offers the potential for
easier co-ordination of inhalation with actuation of the
inhaler. Deposition studies have shown that a higher propor-
tion of the emitted dose from the Respimat inhaler is
delivered to the lungs than from a pMDI or from a multidose
DPI.16,17
The results of a European phase II dose-ranging study on
tiotropium in COPD patients showed that daily doses of
5e20 mg inhaled from the Respimat inhaler were more
effective than placebo in improving trough FEV1 and other
lung function measures after 3 weeks’ treatment, and that
steady-state urinary excretion of tiotropium with the 5 mg
daily dosage from the Respimat inhaler was similar to that
with the 18 mg daily dosage from HandiHaler.18 Further-
more, in a pooled analysis of two crossover studies of iden-
tical design in American and European COPD patients,
tiotropium Respimat 5 mg was similar to tiotropium Handi-
Haler 18 mg with respect to lung function improvement,
pharmacokinetic profile and safety after 4 weeks’ treat-
ment.19 On the basis of these results, a tiotropium dose of
5 mg from the Respimat inhaler was considered to be
comparable to an 18 mg dose from the HandiHaler in
American and European patients with COPD. The objective of
the current studywas to compare the same two treatments in
Japanese COPD patients, to investigate whether the
comparability also applies in this population. The effects of
the two inhalers were compared using measurements of
clinical efficacy, pharmacokinetic, tolerability and safety.Methods
Study design
This phase 2 clinical trial used a randomised, double-blind,
double-dummy, 2-way crossover design, and was conducted
in 27 outpatient centres in Japan. The trial was carried out
in compliance with principles laid down in the Declarationof Helsinki and in accordance with both the International
Conference on Harmonisation (ICH) Harmonised Tripartite
Guideline for GCP and Japanese GCP. The protocol and all
amendments were approved by the local institutional
review board, and all participants gave written informed
consent. The trial is registered as NCT00292448 on
ClinicalTrials.gov registry.
Patients
Japanese men or women were eligible for study entry if
they were aged 40 years or older, had COPD (FEV1 of no
more than 70% predicted normal and ratio of FEV1 to FVC of
no more than 70%), and were current or ex-smokers
(smoking history of >10 pack-years). Predicted normal FEV1
values were calculated according to the standard formula
for Japanese individuals.20 To enter the second treatment
period (Period 2), a patient’s baseline FEV1 reading at the
start of that period had to be within 15% of his or her
reading at the start of the first treatment period. Patients
were excluded if they had a history of asthma or allergic or
atopic disease or, during the month before the screening
visit, had received any specific treatment for such diseases
(e.g. disodium cromoglycate, leukotriene antagonists, or
antihistamines). Other exclusion criteria included a history
of arrhythmias, or myocardial infarction in the previous
year, or heart failure requiring hospital treatment in the
previous 3 years, or treatment with beta-blockers during
the month before the screening visit.Treatments and crossover procedure
After the initial visit for patient screening, all participants
entered a 4-week screening period during which they were
instructed to practice inhalation from the Respimat
inhaler and HandiHaler, using placebo versions of both
test inhalers; patients also received instruction on correct
preparation and inhalation technique for each inhaler. At
the end of this period, patients meeting the entry criteria
were randomly assigned in a 1:1 ratio to either regimen A or
B for a 4-week period (Period 1):
Regimen AZ tiotropium 5 mg inhaled via the Respimat
inhaler (two puffs of 2.5 mg each) plus placebo capsule
inhaled via HandiHaler, both given once daily in the
morning.
Regimen BZ placebo inhaled via the Respimat inhaler
(two puffs) plus tiotropium 18 mg capsule inhaled via
HandiHaler, both given once daily in the morning.
In both groups, the Respimat inhaler was used first and
HandiHaler second (within 3 min of each other). After
Period 1, patients entered a 4-week wash-out period (no
study treatment), and then restarted study treatment for
a further 4 weeks (Period 2), receiving whichever Regimen
(A or B) they did not receive in the first period. For both
treatment periods and the wash-out period, the allowable
variance in duration was 7 days.
The following concomitant medications were permitted
at any time during the study provided the dosage was
stable: inhaled short-acting beta-agonists (SABAs), which
could also be used as rescue medication except on days
when lung function tests were performed; oral or inhaled
230 M. Ichinose et al.corticosteroids; theophylline, and mucolytics. During the
screening period and wash-out period only, the following
additional medications were permitted (again at stable
dosages only): inhaled long-acting beta-agonists (LABAs),
oral and transdermal beta-agonists and inhaled short-acting
anticholinergics.
Assessments
Pulmonary function tests (PFTs) were performed by spirom-
etry at the screening visit to assess patients against screening
criteria. Testingwas repeated at the start and end (Day 1 and
Day 29) of Periods 1 and 2 for efficacy measurements; on
these occasions, tests were done 10 min before dosing of
study medication, and 1, 2 and 3 h post-dose. At each time
point, the highest FEV1 and FVC values were recorded (from
at least 3 attempts). The administration of other broncho-
dilators in the 24 h before the PFT was restricted to avoid
confounding. For each patient, the baseline FEV1 on Day 1 of
Period 2 was required to be within15% of the baseline FEV1
on Day 1 of Period 1. If this requirement was not met, the
patient had up to two additional opportunities to comply,
each within 7 days of the previous PFT.
To measure steady-state pharmacokinetics, blood and
urine samples were taken at the end of both treatment
periods (Day 29). Blood was taken pre-dose (no more than
1 h prior to dosing), then 10 min, 1.5 h and 4 h after dosing.
For each patient, urine samples were combined into two
separate collection periods, for the first 2 h after dosing
and for the period 2e4 h after dosing. Plasma and urine
levels of tiotropium were assayed by HPLC plus tandem
mass spectrometry (HPLCeMS/MS) system, with a lower
limit of quantification of 2.5 pg/ml in plasma samples and
10 pg/ml in urine samples. Steady-state kinetics were
described by the parameters AUCt,ss and Ae0e4,ss, i.e. the
area under the tiotropium concentration-time curve over
the dosing interval t (24 h) and the amount of tiotropium in
the urine in the 4 h after dosing.
Tolerability was assessed by adverse event monitoring
from screening visit to 30 days after the last dose of study
treatment. Any adverse event occurring after the first dose
of a study treatment and up to 30 days after the last dose of
the treatment was assigned to that treatment, as long as
the next study treatment had not started.
At the screening visit and at the end of Periods 1 and 2,
patients underwent physical examination and ECG, and had
blood and urine sampled for haematology, urinalysis, and
routine blood chemistry. Vital signs were measured at all
visits (screening, and start and end of Periods 1 and 2).Endpoints and statistical analysis
The Full Analysis Set (FAS), which consisted of the two
treatment periods where baseline data and post-treatment
data were available, was used for the analyses. The primary
efficacy endpoint was the trough FEV1 response, i.e. the
difference between pre-dose FEV1 on Day 1 of the treat-
ment period and the pre-dose value on Day 29 of the same
period. Using an analysis of covariance (ANCOVA) with
terms for period, treatment and patient as fixed effects,
and baseline FEV1 as a covariate, the null hypothesis testedwas that trough FEV1 response with tiotropium Respimat

was inferior to that with tiotropium HandiHaler. Assuming
that the smallest clinically meaningful difference between
treatments in this measure was 0.05 L, the null hypothesis
could be rejected, i.e. tiotropium Respimat would be non-
inferior to tiotoprium HandiHaler, if the lower 95% confi-
dence limit (CL) for the difference between treatments
(tiotropium Respimat minus tiotropium HandiHaler) was
greater than 0.05 L.
Assuming a standard deviation in paired differences of
trough FEV1 of 0.12 L, 78 patients would need to complete
the study to detect a difference in mean trough FEV1
response between the two study treatments of at least
0.05 L with a significance level of 2.5% (one-sided) and 95%
statistical power.
Secondary efficacy endpoints included the peak and
average bronchodilator responses (measured as both FEV1
and FVC) on Day 1 and Day 29. For both test days, peak
response was the difference between the highest value
recorded during the post-dose PFTs and the period baseline;
average response was the area under the response-time
curve during thefirst 3 h after dosing (AUC0e3h). Estimates for
peak and average responses were adjusted for patient,
period and baseline value. Trough FVC response after 4
weeks, derived in the same way as trough FEV1, was an
additional efficacy endpoint. Analysis of all secondary effi-
cacy endpointswas doneusing ANCOVA in the sameway as for
the primary endpoint, except that a two-tailed 95% confi-
dence interval (CI) around the mean estimate was derived.
Analysis of tolerability, safety and pharmacokinetics
data were done for all patients who had received at least
one dose of study medication (the safety population).
Results
Patient disposition and screening characteristics
Of 184 patients enrolled at the screening visit, 157 met the
criteria for entry to the study. In all, 134 patients
completed the study (full analysis set), and 157 received at
least one dose of study medication (safety population). A
diagram of patient flow through each stage of the study is
shown in Fig. 1.
At the screening visit, the great majority (98.1%) of
COPD patients were men, and the mean age of the sample
was 70.2 years (Table 1). Most were ex-smokers (77.1%).
Although the average time since COPD diagnosis was 5.8
years, mean lung function measures at screening were an
FEV1 of 43.1% predicted normal and FEV1/FVC ratio of
41.9%, and the majority of patients (66.9%) had severe or
very severe COPD, i.e. Stage III or IV as defined by the
Global Initiative for Chronic Obstructive Lung Disease
(GOLD) guidelines.21 These data, together with baseline
values of FEV1 and FVC for the two treatment groups, are
shown in Table 1.
Efficacy
Primary endpoint
Graphs of change in mean FEV1 in the 3 h after inhalation of
tiotropium from each test inhaler show that on Day 1 and
Tiotropium Respimat 
5 µg (76)
Enrolled (184)
Withdrawn (2)
Completed (134)
Period 1
Randomly allocated to one of two treatment sequences (157)
Excluded (27)
Tiotropium HandiHaler 
18 µg (81)
Withdrawn (2)
Withdrawn (8) Withdrawn (8)
Tiotropium HandiHaler 
18 µg (66)
Withdrawn (1)
Period 2
Tiotropium Respimat  
5 µg (71)
Withdrawn (2)
Wash-out (74) Wash-out (79)
Figure 1 Patient flow through study.
Table 1 Characteristics of study participants at screening
(nZ 157 who took at least one dose of study medication)
and spirometry measures at baseline (combined data for
Periods 1 and 2; nZ 147 for both treatments).
Mean value
(standard deviation)
Range
Values at screening visit
Age, y 70.2 (7.5) 43e87
Men/women 154/3 e
Ex-smokers/
smokers, n
121/36 e
Smoking history,
pack-years
60.4 (30.0) 20e150
Time since COPD
diagnosis, y
5.8 (5.0) 0.1e38.0
FEV1, L 1.171 (0.383) 0.35e2.21
FEV1, % predicted 43.1 (13.3) 11e79
FVC, L 2.795 (0.646) 1.17e4.37
FEV1/FVC ratio, % 41.9 (9.7) 19.8e69.7
GOLD stage, n (%):
I 0 (0) e
II 52 (33.1) e
III 81 (51.6) e
IV 24 (15.3) e
Values at baseline
FEV1, L
Tiotropium
Respimat 5 mg
1.072 (0.386) 0.37e2.11
Tiotropium
HandiHaler 18 mg
1.096 (0.381) 0.37e2.10
FVC, L
Tiotropium
Respimat 5 mg
2.614 (0.621) 1.31e4.12
Tiotropium
HandiHaler 18 mg
2.662 (0.656) 1.21e4.40
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very similar for the Respimat inhaler and HandiHaler
(Fig. 2a and b). Compared with the Day 1 baseline (pre-dose
value), the mean pre-dose (trough) FEV1 on Day 29
increased by 0.109 L and 0.101 L for the Respimat inhaler
and HandiHaler, respectively. The mean difference in
trough FEV1 response between the inhalers was 0.008 L
(95% CI, 0.009 to þ0.024 L). As the lower CL was greater
than 0.05 L, tiotropium Respimat was non-inferior to
tiotropium HandiHaler (p< 0.001; Table 2).
In addition, the 95% CI for the mean estimated differ-
ence in trough FEV1 between tiotropium Respimat
 and
tiotropium HandiHaler lay entirely within the range of
0.05 L to þ0.05 L, indicating very similar performance of
the two inhalers according to this efficacy measure.
Secondary efficacy measures
The peak and average (AUC0e3h) FEV1 responses to tio-
tropium Respimat were very similar to those to tiotropium
HandiHaler on Day 1 and Day 29, with no statistically
significant differences between the two inhalers (Table 3).
The changes in FVC in the 3 h after inhalation of tio-
tropium from each test inhaler also show very similar
responses for the two inhalers (Fig. 2c and d). On Day 29, the
adjustedmean trough FVC valuewas higher that the pre-dose
value on Day 1 by 0.213 L and 0.217 L for the Respimat
inhaler and HandiHaler respectively; the difference
between inhalers in trough FVC response (0.004 L) was not
significant (pZ 0.84) (Table 4). For peak FVC responses and
AUC0e3h FVC responses on Day 1 and Day 29, there were also
no significant differences between the two inhalers (Table 4).
Pharmacokinetics
Data from 153 patients was available for pharmacokinetic
analysis. Steady-state plasma concentration-time profilesfor tiotropium were similar for the two inhalers (Fig. 3),
and steady-state tiotropium plasma exposures (AUCt,ss)
were 94.4 and 89.6 pg h/ml (geometric mean values,
nZ 128) for the Respimat inhaler and HandiHaler
respectively, giving an adjusted mean ratio for the
Respimat inhaler to HandiHaler of 105.60%. For steady-
state urinary excretion of unchanged tiotropium in the
first 4 h after dosing, the respective values of Ae0e4,ss
were 342 and 341 ng (nZ 128), giving an adjusted mean
ratio of 102.22%.
The 90% CLs of the adjusted mean ratios (Respimat:
HandiHaler) were 98.00 and 113.78% for AUCt,ss and 92.50
and 112.96 for Ae0e4,ss; both of these lay within the interval
of 80e125%, thus meeting the criterion for therapeutic
equivalence for orally administered drugs. For inhaled
drugs, this finding indicates comparable systemic exposure
with the two inhalers.
Tolerability and safety
Adverse events are summarised in Table 5. The number of
adverse events reported during treatment with tiotropium
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Figure 2 Changes in lung function parameters in the 3 h after dosing in full analysis set (nZ 134): mean FEV1 on Days 1 and 29
(a and b); mean FVC on Days 1 and 29 (c and d).
232 M. Ichinose et al.Respimat (45; 30.6%) was similar to that with tiotropium
HandiHaler (41; 27.9%). The number of patients report-
ing adverse events considered by the investigator to be
related to study treatment was low (4 [2.7%] and 8 [5.4%]
patients during Respimat and HandiHaler treatment
periods respectively). Three patients withdrew from the
treatment phase of the study as a result of adverse
events.Table 2 Non-inferiority analysis for trough FEV1 increase (chan
set. Mean increases are adjusted for effects of patient, period a
N Adjusted mean
increase, L (SE)
M
L
Tiotropium
Respimat 5 mg
134 0.109 (0.006) e
Tiotropium
HandiHaler 18 mg
134 0.101 (0.006) e
Difference, Respimat
minus HandiHaler
134 e 0
Abbreviations: CL, confidence limits; SE, standard error.
a One-sided ANCOVA for non-inferiority.In all, 11 serious adverse events (SAEs) were reported by
ten patients during the two treatment periods, none of
which were considered to be related to study treatment.
The 11 SAEs that occurred (five with Respimat and six with
HandiHaler) were bacterial bronchitis, COPD exacerbation
(4 events), haemorrhoids, oesophageal carcinoma, pneu-
monia,2 pneumothorax and rheumatoid arthritis. No deaths
occurred during the study.ge in pre-dose FEV1 from Day 1 to Day 29) in the full analysis
nd baseline FEV1.
ean difference,
(SE)
95% CL p value for
non-inferioritya
0.097, 0.120 e
0.089, 0.113 e
.008 (0.009) 0.009, 0.024 p< 0.001
Table 3 Summary of peak and average (AUC0e3h) FEV1 responses on Day 1 and Day 29 in the full analysis set. Mean responses
are adjusted for effects of patient, period and baseline FEV1 on Day 1.
Tiotropium Respimat
5 mg (nZ 134)
Tiotropium HandiHaler
18 mg (nZ 134)
Peak FEV1, Day 1, L
Adjusted mean response (95% CL) 0.186 (0.175, 0.196) 0.189 (0.179, 0.199)
Difference, Respimat minus HandiHaler (95% CL) 0.003 (0.018, 0.011)
p value for difference between inhalersa 0.6481
Peak FEV1, Day 29, L
Adjusted mean response (95% CL) 0.220 (0.208, 0.232) 0.205 (0.193, 0.217)
Difference, Respimat minus HandiHaler (95% CL) 0.015 (0.002, 0.032)
p value for difference between inhalersa 0.0925
FEV1 AUC0e3h, Day 1, L
Adjusted mean response (95% CL) 0.119 (0.111, 0.127) 0.122 (0.114, 0.130)
Difference, Respimat minus HandiHaler (95% CL) 0.003 (0.014, 0.009)
p value for difference between inhalersa 0.6358
FEV1 AUC0e3h, Day 29, L
Adjusted mean response (95% CL) 0.166 (0.155, 0.177) 0.151 (0.140, 0.162)
Difference, Respimat minus HandiHaler (95% CL) 0.015 (0.001, 0.030)
p value for difference between inhalersa 0.0679
Abbreviations: CL, confidence limits; SE, standard error.
a Two-sided ANCOVA.
Tiotropium in Respimat and HandiHaler in Japanese COPD patients 233In the listing of adverse events by preferred term, the
most common events were nasopharyngitis (22 patients)
and COPD exacerbation (10 patients). Dry mouth was
reported by 5 patients. These and other common events,
i.e. those occurring in 2% of more of patients on either
inhaler, are listed in Table 5.
No clinically important drug-related changes were noted
in the assessments of vital signs, ECG and laboratory test
variables.Discussion
In this study, we have shown that a daily tiotropium dose of
5 mg inhaled via the Respimat inhaler was similar to a dose
of 18 mg inhaled from HandiHaler in terms of pulmonary
function improvement and pharmacokinetics when both
were given for a period of 4 weeks. As well as producing an
acute bronchodilator effect after each daily dose, 4 weeks’
treatment with tiotropium inhaled from both test inhalers
was associated with an improvement in airway calibre as
shown by an increase of roughly 100 ml in trough (pre-dose)
FEV1 over the period from Day 1 to Day 29. On the basis of
this efficacy measure, tiotropium Respimat was demon-
strated to be non-inferior to tiotropium HandiHaler at the
doses studied in this trial (p< 0.001).
The similar clinical performance of tiotropium Respimat
5 mg and tiotropium HandiHaler 18 mg was confirmed by
other spirometry measurements. The trough FVC at Day 29
was roughly 200 ml higher than the corresponding value on
Day 1 with both inhalers and for this measure, as well as for
peak andaverage (AUC0e3h) FEV1 andFVC results, differences
between the two inhalers were not statistically significant.
Our efficacy findings are in line with the results of a dose-
ranging study that compared lung function after 3 weeks’treatment with tiotropium HandiHaler 18 mg and a range of
tiotropium doses from the Respimat inhaler.18 They also
agree closely with a comparison done in European and North
American COPD patients who received two different daily
doses of tiotropium from the Respimat inhaler (5 and 10 mg)
and tiotropium 18 mg from HandiHaler, each for 4 weeks in
two crossover studies of identical design.19 Pooled analysis of
those studies demonstrated non-inferiority of tiotropium
Respimat 5 mg to tiotropium HandiHaler 18 mg for the
primary efficacy variable of trough FEV1, and also showed
trough FEV1 responses to be statistically significantly higher
with tiotropium Respimat 5 mg, although the difference was
small and of questionable clinical relevance.
Until now, no studies have been published on tiotropium
pharmacokinetics in Japanese individuals (COPD patients or
volunteers). Average tiotropium plasma concentrations and
urinary excretion of tiotropium at steady-state (Day 29) were
very similar for tiotropium Respimat and tiotropium Handi-
Haler. When adjusted mean ratios (Respimat: Handi-
Haler) were calculated for both parameters, the associated
90% CIs werewithin the interval of 80e125%,whichmeets the
criterion for demonstrating therapeutic equivalence for
orally administered drugs. The pooled analysis of the twin
crossover studies mentioned above 19 also found that
systemic exposures for tiotropium Respimat 5 mg and tio-
tropium HandiHaler 18 mg were similar, although urinary
excretion of tiotropium was 26% higher in the tiotropium
Respimat 5 mg arm than in the tiotropiumHandiHaler 18 mg
arm.
The number and type of adverse events reported in the
current study did not indicate any difference in the tolera-
bility of tiotropium Respimat and tiotropium HandiHaler,
and safety assessments (vital signs, ECG and laboratory test
values) did not suggest any adverse responses to either of the
study treatments. These results are in line with those
Table 4 Summary of trough, peak and average (AUC0e3h) FVC responses, in the full analysis set. Mean responses are adjusted
for effects of patient, period and baseline FVC on Day 1.
Tiotropium Respimat
5 mg (nZ 134)
Tiotropium HandiHaler
18 mg (nZ 134)
Trough FVC, L
Adjusted mean increase, Day 29 minus Day 1 (95% CL) 0.213 (0.186, 0.241) 0.217 (0.190, 0.245)
Difference, Respimat minus HandiHaler (95% CL) 0.004 (0.044, 0.036)
p value for difference between inhalersa 0.8384
Peak FVC, Day 1, L
Adjusted mean response (95% CL) 0.383 (0.359, 0.407) 0.409 (0.386, 0.433)
Difference, Respimat minus HandiHaler (95% CL) 0.026 (0.060, 0.008)
p value for difference between inhalersa 0.1278
Peak FVC, Day 29, L
Adjusted mean response (95% CL) 0.424 (0.398, 0.450) 0.411 (0.385, 0.437)
Difference, Respimat minus HandiHaler (95% CL) 0.013 (0.024, 0.049)
p value for difference between inhalersa 0.4973
FVC AUC0e3h, Day 1, L
Adjusted mean response (95% CL) 0.250 (0.230, 0.269) 0.272 (0.252, 0.291)
Difference, Respimat minus HandiHaler (95% CL) 0.022 (0.050, 0.006)
p value for difference between inhalersa 0.1219
FVC AUC0e3h, Day 29, L
Adjusted mean response (95% CL) 0.326 (0.303, 0.350) 0.316 (0.292, 0.339)
Difference, Respimat minus HandiHaler (95% CL) 0.010 (0.023, 0.044)
p value for difference between inhalersa 0.5414
Abbreviations: CL, confidence limits; SE, standard error.
a Two-sided ANCOVA.
234 M. Ichinose et al.reported from the pooled crossover results in European and
US patients.19 In our study, nasopharyngitis, COPD exacer-
bation and dry mouth were the three most common adverse
events, which is consistent with previous experience from
clinical trials of tiotropium.22
Taken together, the results of our study show that the
Respimat inhaler is a more efficient inhaler than Handi-
Haler. A daily dose of only 5 mg produces similar efficacy and
pharmacokinetics to a dose more than threefold higher fromTime after d
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Figure 3 Change in arithmetic mean plasma concentrations of
deviations.HandiHaler, and tolerability and safety profiles are similar.
Deposition studies have shown that a higher proportion of the
dose emitted from the Respimat inhaler is delivered to the
lungs compared with pMDIs and a multidose DPI.16,17 In
a clinical trial of COPD patients, this allowed the nominal
dose of bronchodilator from a pMDI to be reduced by 50%
while maintaining efficacy and safety.23
Although the protocol of our study allowed inclusion of
men andwomen, the full analysis set included only 3 women.osing (hours)
432
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tiotropium after dosing on Day 29. Error bars show standard
Table 5 Summary of adverse events during study. Events
that occurred in at least 2% of patients in either group are
listed by preferred term.
Number of patients
reporting (n, %)
Tiotropium
Respimat
Tiotropium
HandiHaler
All patients 147 (100) 147 (100)
Any adverse event 45 (30.6) 41 (27.9)
Nasopharyngitis 13 (8.8) 9 (6.1)
COPD exacerbation 6 (4.1) 4 (2.7)
Dry mouth 2 (1.4) 3 (2.0)
Diarrhoea 1 (0.7) 3 (2.0)
Rash 0 (0) 3 (2.0)
Any drug-related
adverse eventa
4 (2.7) 8 (5.4)
Adverse events leading
to discontinuation
1 (0.7) 2 (1.4)
Serious adverse events 4 (2.7) 6 (4.1)
a As judged by the investigator.
Tiotropium in Respimat and HandiHaler in Japanese COPD patients 235This is not unexpected, firstly because the smoking rate in
Japan is much higher in men than in women, and secondly
because Japanese women are generally reluctant to enrol in
clinical trials, not only in COPD but also in other diseases.
Although placebo inhalers were used in our study to conceal
the identity of the active inhaler, there was no all-placebo
arm in the study, in contrast to the RespimateHandiHaler
comparison studies in Europe and US patients. In that analysis
however, all three active treatment arms were found to be
associated with significantly better lung function than
placebo.19
In conclusion, tiotropium Respimat 5 mg was shown to
have similar efficacy and safety as tiotropium HandiHaler
18 mg when used for the treatment of Japanese patients with
COPD, and the 90% confidence intervals of AUC and Ae ratios
(Respimat: HandiHaler) lay within the interval of 80e125%.Acknowledgements
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